10543179

4 known cases. View patent page →

Cases
4
Active
3
1 closed
Filed
2020–2021
Top venue
D. Delaware
2 cases

Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC et al.

Discovery active through mid-2022; final disposition unverified
Docket:
1:21-cv-00645

Suit against Handa entities asserting the '405 patent and also US 10,543,179. Handa sought summary judgment on the '405 patent after the Federal Circuit's June 2022 invalidation; final disposition not verified.

Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. et al.

active
Docket:
1:20-cv-00133
Filed:
2020-01-28

Hatch-Waxman/ANDA patent infringement action by Novartis against HEC and related entities concerning generic fingolimod 0.5 mg capsules. Consolidated with 1:21-cv-01530 and 1:23-cv-00026; claim construction was decided on April 6, 2023 and merits briefing was ongoing.

Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC et al.

dismissed
Docket:
3:21-cv-03397 / 5:21-cv-03397
Filed:
2021-05-06

Protective safety suit filed in the Northern District of California two days after the Delaware Handa suit, asserting the same two patents. Dismissed after the October 2022 Handa settlement.

Case 1:23-cv-00026 — U.S. District Court, District of Delaware

presumably active
Docket:
1:23-cv-00026
Patents:10543179

Listed on Google Patents as litigation involving US Patent 10,543,179 and consolidated with 1:20-cv-00133. Appears to be part of the HEC consolidated fingolimod ANDA litigation, but parties and filing date were not confirmed.